Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRY005
MIFTS: 53

Cryptococcosis

Categories: Rare diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cryptococcosis

About this section

MalaCards integrated aliases for Cryptococcosis:

Name: Cryptococcosis 12 76 53 59 55 3 3 44 15
Infection by Cryptococcus Neoformans 73
Cryptococcus Neoformans Infection 12
Busse-Buschke's Disease 12
European Cryptococcosis 12
Cryptococcal Infection 12
Torulosis 12
Torula 12

Characteristics:

Orphanet epidemiological data:

59
cryptococcosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:12053
ICD10 33 B45 B45.9
ICD9CM 35 117.5
MeSH 44 D003453
NCIt 50 C2967
Orphanet 59 ORPHA1546
UMLS via Orphanet 74 C0010414
ICD10 via Orphanet 34 B45.1 B45.2 B45.3 more
MESH via Orphanet 45 D003453
UMLS 73 C0010414
Sources

Summaries for Cryptococcosis

About this section
CDC : 3 Cryptococcus gattii is a fungus that lives in the environment in many tropical and sub-tropical areas of the world as well as British Columbia and the U.S. Pacific Northwest. C. gattii cryptococcosis is a rare infection that people can get after breathing in the microscopic fungus. The infection can affect the lungs, central nervous system, or both.

MalaCards based summary : Cryptococcosis, also known as infection by cryptococcus neoformans, is related to cryptococcal meningitis and meningitis. An important gene associated with Cryptococcosis is SELL (Selectin L), and among its related pathways/superpathways are Innate Immune System and NF-kappaB Signaling. The drugs Amphotericin B and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, liver and testes, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An opportunistic mycosis that results in fungal infection and has material basis in Cryptococcus neoformans or Cryptococcus gattii.

Wikipedia : 76 Cryptococcosis, also known as cryptococcal disease, is a potentially fatal fungal disease. It is caused... more...

Sources

Related Diseases for Cryptococcosis

About this section

Diseases related to Cryptococcosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 cryptococcal meningitis 32.7 IFNG MBL2
2 meningitis 30.2 FCGR2A IFNG MBL2 TLR9
3 coccidioidomycosis 30.0 CARD9 MBL2
4 candidiasis 29.7 CARD9 IFNG PLB1
5 lymphopenia 29.5 IFNG SELL UNC119
6 aspergillosis 29.0 IFNG IL4 MBL2 TLR9
7 toxoplasmosis 28.9 IFNG IL4 TLR9
8 bronchiolitis 28.9 IFNG IL4 TLR9
9 leishmaniasis 28.9 IFNG IL4 TLR9
10 colitis 28.8 IFNG IL4 TLR9
11 pulmonary tuberculosis 28.7 IFNG IL4 MBL2 TLR9
12 systemic lupus erythematosus 27.4 FCGR2A FCGR3A FCGR3B IFNG IL4 MBL2
13 fixed drug eruption 10.8 IFNG SELL
14 transient neonatal neutropenia 10.7 FCGR3A FCGR3B
15 spastic paraplegia 32, autosomal recessive 10.7 FCGR3A FCGR3B
16 rheumatic myocarditis 10.7 FCGR3A FCGR3B
17 adult dermatomyositis 10.7 MBL2 TLR9
18 orbital plasma cell granuloma 10.6 FCGR3A FCGR3B
19 adult lymphoma 10.6 FCGR2A FCGR3A
20 meningococcal meningitis 10.6 MBL2 TLR9
21 myositis fibrosa 10.6 IFNG TLR9
22 chronic nk-cell lymphocytosis 10.6 FCGR3A FCGR3B
23 chronic orbital inflammation 10.5 FCGR3A FCGR3B
24 neisseria meningitidis infection 10.5 FCGR2A MBL2
25 kawasaki disease 10.5 FCGR2A MBL2 SELL
26 diffuse infiltrative lymphocytosis syndrome 10.4 FCGR3A FCGR3B
27 plasmodium falciparum malaria 10.3 FCGR2A IFNG TLR9
28 fungal meningitis 10.3 IFNG UNC119
29 exanthema subitum 10.2 FCGR3A FCGR3B
30 mycoplasmal pneumonia 10.2 IFNG IL4
31 behcet syndrome 10.2 IFNG MBL2 SELL TLR9
32 hyperlucent lung 10.2 IFNG IL4
33 b-cell growth factor 10.1 IFNG IL4
34 baylisascariasis 10.1 IFNG IL4
35 ovarian cystic teratoma 10.1 FCGR3A FCGR3B
36 penicillin allergy 10.1 IFNG IL4
37 endotheliitis 10.1
38 atopic keratoconjunctivitis 10.1 IFNG IL4
39 lung cancer 10.0
40 microscopic colitis 10.0 IFNG IL4
41 cellulitis 10.0
42 urinary schistosomiasis 10.0 IFNG IL4
43 buruli ulcer 10.0 IFNG IL4
44 toxic oil syndrome 10.0 IFNG IL4
45 arthritis 10.0
46 acquired immunodeficiency syndrome 10.0
47 immunodeficiency with hyper-igm, type 1 10.0
48 rheumatoid arthritis 10.0
49 hyper ige syndrome 9.9 IFNG IL4
50 lymphoma 9.9

Comorbidity relations with Cryptococcosis via Phenotypic Disease Network (PDN):


Acute Cystitis Cryptococcal Meningitis
Deficiency Anemia

Graphical network of the top 20 diseases related to Cryptococcosis:



Diseases related to Cryptococcosis
Sources

Symptoms & Phenotypes for Cryptococcosis

About this section

MGI Mouse Phenotypes related to Cryptococcosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.61 TLR9 CARD9 CLEC6A FCGR2A FCGR3B IFNG
2 immune system MP:0005387 9.28 SELL TLR9 CARD9 CLEC6A FCGR2A FCGR3B
Sources

Drugs & Therapeutics for Cryptococcosis

About this section

Drugs for Cryptococcosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1397-89-3 14956 5280965
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
3
Fluconazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 86386-73-4 3365
4
Voriconazole Approved, Investigational Phase 4 137234-62-9 71616
5
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 84625-61-6 55283
6
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
7
Lamivudine Approved, Investigational Phase 4,Not Applicable 134678-17-4 60825
8
Stavudine Approved, Investigational Phase 4,Not Applicable 3056-17-5 18283
9
Zidovudine Approved Phase 4 30516-87-1 35370
10
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
11
Nevirapine Approved Phase 4,Not Applicable 129618-40-2 4463
12
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
14 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Liposomal amphotericin B Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Steroid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Pharmaceutical Solutions Phase 4,Phase 3
26 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
27
Hydroxyitraconazole Phase 4,Phase 3,Phase 2,Not Applicable
28 Anti-HIV Agents Phase 4,Phase 3,Not Applicable
29 Anti-Retroviral Agents Phase 4,Phase 3,Not Applicable
30 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Cytochrome P-450 CYP3A Inducers Phase 4,Not Applicable
32 Nucleic Acid Synthesis Inhibitors Phase 4,Not Applicable
33 Reverse Transcriptase Inhibitors Phase 4,Not Applicable
34 Atazanavir Sulfate Phase 4,Phase 3
35 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
36 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
37
protease inhibitors Phase 4,Phase 3,Phase 2
38
Tenofovir Phase 4 147127-20-6 464205
39
Flucytosine Approved, Investigational Phase 2, Phase 3,Not Applicable 2022-85-7 3366
40
Posaconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 171228-49-2 147912
41
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
42
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
43
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
44
Sertraline Approved Phase 3 79617-96-2 68617
45 tannic acid Approved, Nutraceutical Phase 3
46 Antimetabolites Phase 2, Phase 3,Not Applicable
47 Analgesics Phase 3
48 Analgesics, Non-Narcotic Phase 3
49 Interleukin-2 Phase 3
50 Peripheral Nervous System Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
2 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex Completed NCT01656382 Phase 4 ABLC
3 Operational Research for Cryptococcal Antigen Screening Completed NCT01535469 Phase 4 Fluconazole
4 A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Completed NCT00647907 Phase 4 Voriconazole
5 Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis Completed NCT00976040 Phase 4
6 Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection Completed NCT01198236 Phase 4 Itraconazole
7 Cryptococcal Optimal ART Timing Trial Completed NCT01075152 Phase 4 efavirenz
8 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
9 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis Unknown status NCT01125644 Phase 3 SPK-843
10 Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine
11 Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041) Completed NCT00034658 Phase 3 Posaconazole
12 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
13 Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095) Completed NCT00034632 Phase 3 Posaconazole oral suspension
14 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
15 Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
16 PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) Completed NCT01099579 Phase 3 Atazanavir powder;Ritonavir oral solution;Atazanavir capsules;Ritonavir capsules
17 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
18 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
19 Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis Completed NCT01802385 Phase 3 Sertraline
20 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC Completed NCT01589289 Phase 3
21 Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis Not yet recruiting NCT03471988 Phase 3 AK1820;Voriconazole
22 Cryptococcal Antigen Screening Plus Sertraline Terminated NCT03002012 Phase 3 Sertraline;Placebo Oral Tablet;Fluconazole
23 PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893) Completed NCT00034671 Phase 2 Posaconazole oral suspension
24 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals Completed NCT00885703 Phase 1, Phase 2 Fluconazole;Amphotericin B
25 Dexamethasone in Cryptococcal Meningitis Completed NCT00000776 Phase 2 Flucytosine;Fluconazole;Amphotericin B;Dexamethasone
26 Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis Completed NCT00145249 Phase 2 Amphotericin B;Fluconazole
27 Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis Completed NCT00012467 Phase 2 Itraconazole;Flucytosine;Fluconazole;Amphotericin B;Interferon gamma-1b
28 Treatment With Tamoxifen in Cryptococcal Meningitis Recruiting NCT03112031 Phase 2 Tamoxifen;Amphotericin B;Fluconazole
29 Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00847678 Phase 2
30 Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00324025 Phase 2 Mycograb;placebo
31 SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy Completed NCT00000677 Phase 1 SCH 39304
32 Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report Completed NCT02955862 Phase 1
33 The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis Completed NCT00002316 Phase 1 Lobradimil;Amphotericin B
34 Clinical Trial of Pulmonary Cryptococcosis in China Unknown status NCT02503449
35 Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis Unknown status NCT02136030 Not Applicable Liposomal amphotericin B;Amphotericin B-deoxycholate
36 Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection Completed NCT00001701
37 Idiopathic CD4 Lymphocytopenia Completed NCT02113930
38 A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00000639 Not Applicable Itraconazole;Flucytosine;Fluconazole;Amphotericin B
39 A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients Completed NCT00002438 Not Applicable Itraconazole
40 Nevirapine Levels and Fluconazole Completed NCT00309582
41 A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS Completed NCT00002294 Not Applicable Fluconazole
42 Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00000708 Not Applicable Flucytosine;Fluconazole;Amphotericin B
43 A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. Completed NCT00002113 Not Applicable Flucytosine;Fluconazole
44 A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B Completed NCT00002306 Not Applicable Fluconazole
45 Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002076 Not Applicable Fluconazole
46 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002074 Not Applicable Fluconazole;Amphotericin B
47 Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00002019 Not Applicable Amphotericin B, Lipid-based;Amphotericin B
48 A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis Completed NCT00002305 Not Applicable Flucytosine;Fluconazole;Amphotericin B
49 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002075 Not Applicable Flucytosine;Fluconazole;Amphotericin B
50 A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002068 Not Applicable Fluconazole;Amphotericin B

Search NIH Clinical Center for Cryptococcosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: cryptococcosis

Sources

Genetic Tests for Cryptococcosis

About this section
Sources

Anatomical Context for Cryptococcosis

About this section

MalaCards organs/tissues related to Cryptococcosis:

41
Lung, Liver, Testes, Bone, Brain, T Cells, Kidney
Sources

Publications for Cryptococcosis

About this section

Articles related to Cryptococcosis:

(show top 50) (show all 712)
# Title Authors Year
1
Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis. ( 29740519 )
2018
2
The status of cryptococcosis in Latin America. ( 29641639 )
2018
3
Diagnostic and therapeutic strategies in cryptococcosis: impact on outcome. ( 29742199 )
2018
4
Disseminated cryptococcosis in HIV negative patient. ( 29754135 )
2018
5
Additive potential of combination therapy against cryptococcosis employing a novel amphotericin B and fluconazole loaded dual delivery system. ( 29653177 )
2018
6
Outcomes of cryptococcosis in renal transplant recipients in a less-resourced health care system. ( 29677399 )
2018
7
Miliary tuberculosis with co-existing pulmonary cryptococcosis in non-HIV patient without underlying diseases: a case report. ( 29338706 )
2018
8
Tuberculous peritonitis and pleurisy accompanied by pulmonary cryptococcosis: A case report. ( 29756504 )
2018
9
Variability in innate host immune responses to cryptococcosis. ( 29668826 )
2018
10
Multifocal Soft Tissue Cryptococcosis in a Renal Transplant Recipient: The Importance of Suspecting Atypical Pathogens in the Immunocompromised Host. ( 29957160 )
2018
11
Antibody and B Cell Subset Perturbations in Human Immunodeficiency Virus-Uninfected Patients With Cryptococcosis. ( 29354657 )
2018
12
Pulmonary cryptococcosis mimicking neoplasm in terms of uptake PET/CT. ( 29540949 )
2018
13
Neglected disease, neglected populations: the fight against Cryptococcus and cryptococcosis. ( 29668824 )
2018
14
Disseminated cryptococcosis presenting initially as lower limb cellulitis in a renal transplant recipient - a case report. ( 29374464 )
2018
15
Isolated iliac cryptococcosis in an immunocompetent patient. ( 29596420 )
2018
16
Treatment of cryptococcosis in non-HIV immunocompromised patients. ( 29738314 )
2018
17
Cutaneous cryptococcosis. ( 29735406 )
2018
18
Cryptococcosis with bird's eye manifestation: A case report. ( 29697086 )
2018
19
Diminished CD40L expression on T-cells in a case of disseminated cryptococcosis. ( 29567905 )
2018
20
Clinical features and radiological characteristics of pulmonary cryptococcosis. ( 29848126 )
2018
21
Epidemiological trends of cryptococcosis in Italy: Molecular typing and susceptibility pattern of Cryptococcus neoformans isolates collected during a 20-year period. ( 29373716 )
2018
22
Ulcerative cellulitis of the arm: a case of primary cutaneous cryptococcosis. ( 29630156 )
2018
23
Duodenum Cryptococcosis Mimicking Primary Duodenum Cancer on PET/CT Imaging. ( 29538024 )
2018
24
Cryptococcosis as a cause of nephrotic syndrome? A case report and review of the literature. ( 29942774 )
2018
25
Cutaneous Cryptococcosis Mimicking Leishmaniasis. ( 29342402 )
2018
26
Disseminated cryptococcosis associated with administration of eculizumab. ( 29895518 )
2018
27
A case of disseminated cryptococcosis with necrotizing fasciitis in a non-HIV patient. ( 29123908 )
2017
28
Cryptococcus (Cryptococcosis), Cutaneous ( 28846364 )
2017
29
Disseminated cryptococcosis with skin lesions: report of a case series. ( 29267451 )
2017
30
Disseminated cryptococcosis presenting as cellulitis. ( 27779149 )
2017
31
Disseminated Cryptococcosis with Severe Increased Intracranial Pressure Complicated with Cranial Nerve Palsy in a Child. ( 29189676 )
2017
32
Evaluation of a Cryptococcal antigen Lateral Flow Assay in serum and cerebrospinal fluid for rapid diagnosis of cryptococcosis in Colombia. ( 29267584 )
2017
33
Disseminated Cryptococcosis in an Immunocompetent Child. ( 28044302 )
2017
34
Pleuro-pulmonary Cryptococcosis without Pleural Effusion. ( 28792175 )
2017
35
Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis. ( 28721333 )
2017
36
First report of two cases of cryptococcosis in Tripoli, Libya, infected with Cryptococcus neoformans isolates present in the urban area. ( 28576330 )
2017
37
Vaccination with Recombinant<i>Cryptococcus</i>Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. ( 29184017 )
2017
38
Clinical Diversity of CNS Cryptococcosis. ( 29319242 )
2017
39
Dermoscopic observations in disseminated cryptococcosis with cutaneous involvement. ( 29224242 )
2017
40
Clinical features of pulmonary cryptococcosis among patients with different levels of peripheral blood CD4<sup>+</sup>T lymphocyte counts. ( 29237413 )
2017
41
Disseminated cryptococcosis with recurrent multiple abscesses in an immunocompetent patient: a case report and literature review. ( 28558705 )
2017
42
Image Gallery: Cutaneous presentation of disseminated cryptococcosis in a patient with undiagnosed HIV infection. ( 28940286 )
2017
43
Disseminated cryptococcosis as a complication of lupus nephritis. ( 29265061 )
2017
44
Cryptococcus (Cryptococcosis) ( 28613714 )
2017
45
Tuberculosis/cryptococcosis co-infection in China between 1965 and 2016. ( 28831193 )
2017
46
Cryptococcosis in patients with hematological diseases: a 14-year retrospective clinical analysis in a Chinese tertiary hospital. ( 28673256 )
2017
47
Multicentric Cryptococcosis in a Congo African Grey Parrot ( Psittacus erithacus erithacus). ( 29327953 )
2017
48
Acridine orange fluorescent microscopy is more sensitive than India ink light microscopy in the rapid detection of cryptococcosis among CrAg positive HIV patients. ( 28750078 )
2017
49
Laryngeal Cryptococcosis Associated With Inhaled Corticosteroid Use: Case Reports and Literature Review. ( 29209614 )
2017
50
Cryptococcosis in patients with diabetes mellitus II in mainland China: 1993-2015. ( 28857298 )
2017
Sources

Variations for Cryptococcosis

About this section
Sources

Expression for Cryptococcosis

About this section
Search GEO for disease gene expression data for Cryptococcosis.
Sources

Pathways for Cryptococcosis

About this section

Pathways related to Cryptococcosis according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.7 CARD9 CLEC6A FCGR2A FCGR3A FCGR3B IFNG
2
NF-kappaB Signaling 4
12.31 CARD9 IFNG IL4 TLR9
3
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.25 FCGR3A FCGR3B IFNG IL4
4
C-type lectin receptor signaling pathway 37
Show member pathways
 11.96 CARD9 CLEC6A TLR9
5
Bacterial infections in CF airways 22
Show member pathways
 11.93 IFNG IL4 TLR9
6
Phagosome 37
11.85 FCGR2A FCGR3A FCGR3B MBL2
7
Toxoplasmosis 37
Show member pathways
 11.83 FCGR2A FCGR3A FCGR3B IFNG IL4
8
Spinal Cord Injury 1
11.77 FCGR2A IFNG IL4
9
Osteoclast differentiation 37
11.73 FCGR2A FCGR3A FCGR3B IFNG
10
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.62 FCGR2A IFNG IL4 SELL
11
Phagocytosis of Microbes 64
11.56 FCGR2A FCGR3B TLR9
12
Dendritic Cells Developmental Lineage Pathway 65
11.48 IFNG SELL TLR9
13
Tuberculosis 37
11.35 CARD9 FCGR2A FCGR3A FCGR3B IFNG TLR9
14
Inflammatory Response Pathway 1
11.09 IFNG IL4
15
Development and heterogeneity of the ILC family 1
11.07 IFNG IL4
16
Cytokines and Inflammatory Response 1
11.03 IFNG IL4
17
Staphylococcus aureus infection 37
11 FCGR2A FCGR3A FCGR3B MBL2
18
OX40 Pathway 64
10.94 IFNG IL4
Sources

GO Terms for Cryptococcosis

About this section

Cellular components related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule membrane GO:0030667 8.8 FCGR2A FCGR3B SELL

Biological processes related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.46 FCGR3A FCGR3B IFNG IL4
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.13 CARD9 CLEC6A TLR9
3 positive regulation of interleukin-12 production GO:0032735 8.62 IFNG TLR9

Molecular functions related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 8.8 FCGR2A FCGR3A FCGR3B
Sources

Sources for Cryptococcosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....